147 related articles for article (PubMed ID: 35839733)
1. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer.
Kim CG; Hong M; Jeung HC; Lee G; Chung HC; Rha SY; Kim HS; Lee CK; Lee JH; Han Y; Kim JH; Lee SY; Kim H; Shin SJ; Baek SE; Jung M
Eur J Cancer; 2022 Sep; 172():387-399. PubMed ID: 35839733
[TBL] [Abstract][Full Text] [Related]
2. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
[TBL] [Abstract][Full Text] [Related]
3. Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer.
Aoki M; Shoji H; Nagashima K; Imazeki H; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Higuchi K; Boku N
ESMO Open; 2019; 4(3):e000488. PubMed ID: 31231567
[TBL] [Abstract][Full Text] [Related]
4. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
[TBL] [Abstract][Full Text] [Related]
5. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
Kas B; Talbot H; Ferrara R; Richard C; Lamarque JP; Pitre-Champagnat S; Planchard D; Balleyguier C; Besse B; Mezquita L; Lassau N; Caramella C
JAMA Oncol; 2020 Jul; 6(7):1039-1046. PubMed ID: 32525513
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.
Sasaki A; Nakamura Y; Mishima S; Kawazoe A; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Akimoto T; Shitara K
Gastric Cancer; 2019 Jul; 22(4):793-802. PubMed ID: 30627987
[TBL] [Abstract][Full Text] [Related]
7. Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting.
Kanjanapan Y; Guduguntla G; Varikara AK; Szajer J; Yip D; Cockburn J; Fadia M
Technol Cancer Res Treat; 2023; 22():15330338231209129. PubMed ID: 37885403
[No Abstract] [Full Text] [Related]
8. Hyperprogressive Disease Caused by PD-1 Inhibitors for the Treatment of Pan-Cancer.
Chen S; Gou M; Yan H; Fan M; Pan Y; Fan R; Qian N; Dai G
Dis Markers; 2021; 2021():6639366. PubMed ID: 34239621
[TBL] [Abstract][Full Text] [Related]
9. Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer.
Chen S; Han L; Guo S; Tan Z; Dai G
Hum Vaccin Immunother; 2023 Aug; 19(2):2252692. PubMed ID: 37675466
[TBL] [Abstract][Full Text] [Related]
10. Proposal for multiple new lesions as complement of hyperprogressive disease in NSCLC patients treated with PD-1/PD-L1 immunotherapy.
Wang M; Huang H; Xu Z; Li Z; Shen L; Yu Y; Lu S
Lung Cancer; 2022 Nov; 173():28-34. PubMed ID: 36116167
[TBL] [Abstract][Full Text] [Related]
11. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
Champiat S; Dercle L; Ammari S; Massard C; Hollebecque A; Postel-Vinay S; Chaput N; Eggermont A; Marabelle A; Soria JC; Ferté C
Clin Cancer Res; 2017 Apr; 23(8):1920-1928. PubMed ID: 27827313
[No Abstract] [Full Text] [Related]
12. Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.
Hwang I; Park I; Yoon SK; Lee JL
Clin Genitourin Cancer; 2020 Apr; 18(2):e122-e133. PubMed ID: 31837940
[TBL] [Abstract][Full Text] [Related]
13. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/PD-L1 blockade for cancer treatment.
Ren Z; Yang K; Zhu L; Yin D; Zhou Y
Int Immunopharmacol; 2024 May; 132():111934. PubMed ID: 38574701
[TBL] [Abstract][Full Text] [Related]
15. Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies.
Zhao LP; Hu JH; Hu D; Wang HJ; Huang CG; Luo RH; Zhou ZH; Huang XY; Xie T; Lou JS
Biomed Pharmacother; 2022 Jun; 150():112949. PubMed ID: 35447545
[TBL] [Abstract][Full Text] [Related]
16. PD-1
Kamada T; Togashi Y; Tay C; Ha D; Sasaki A; Nakamura Y; Sato E; Fukuoka S; Tada Y; Tanaka A; Morikawa H; Kawazoe A; Kinoshita T; Shitara K; Sakaguchi S; Nishikawa H
Proc Natl Acad Sci U S A; 2019 May; 116(20):9999-10008. PubMed ID: 31028147
[TBL] [Abstract][Full Text] [Related]
17. Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).
Liu J; Wu Q; Wu S; Xie X
Clin Transl Oncol; 2021 Sep; 23(9):1782-1793. PubMed ID: 33847923
[TBL] [Abstract][Full Text] [Related]
18. Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan.
Aoki M; Kadowaki S; Takahashi N; Suzuki T; Oshima K; Ando T; Yamamoto Y; Kawakami K; Kito Y; Matsumoto T; Shimozaki K; Miyazaki Y; Yamaguchi T; Nagase M; Tamura T; Amanuma Y; Esaki T; Miura Y; Akiyoshi K; Baba E; Makiyama A; Negoro Y; Nakashima K; Sugimoto N; Nagashima K; Shoji H; Boku N
Gastric Cancer; 2023 Jan; 26(1):132-144. PubMed ID: 36316527
[TBL] [Abstract][Full Text] [Related]
19. Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy.
Zhang L; Wu L; Chen Q; Zhang B; Liu J; Liu S; Mo X; Li M; Chen Z; Chen L; You J; Jin Z; Chen X; Zhou Z; Zhang S
EClinicalMedicine; 2021 Jan; 31():100673. PubMed ID: 33554079
[TBL] [Abstract][Full Text] [Related]
20. Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
Yumita S; Ogasawara S; Nakagawa M; Maruta S; Okubo T; Itokawa N; Iino Y; Obu M; Haga Y; Seki A; Kogure T; Ishino T; Ogawa K; Fujiwara K; Iwanaga T; Fujita N; Sakuma T; Kojima R; Kanzaki H; Koroki K; Inoue M; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Saito T; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Itobayashi E; Atsukawa M; Koma Y; Azemoto R; Ito K; Mizumoto H; Kato J; Kato N
BMC Gastroenterol; 2023 Mar; 23(1):101. PubMed ID: 37003980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
